GlassScriptPhysician profile
Mona G Mehta
NPI 1184917700
$32,811.83
in general payments reported to CMS, 2019-2025
83 companies · $6,221 in 2025
The $6,221 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,997 · 2020: $2,774 · 2021: $3,710 · 2022: $4,925 · 2023: $6,963 · 2024: $5,223 · 2025: $6,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Consulting Fee: $1,800 · Education: $253 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,292.57 |
| Consulting Fee | $1,800.00 |
| Education | $253.47 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $3,932.30 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $3,449.44 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $3,154.75 | 2019-2025 | |
| Ucb, INC. | $2,762.17 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $1,914.29 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Biogen, INC. | $1,477.11 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Alexion Pharmaceuticals, INC. | $1,341.74 | 2019-2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $1,186.01 | 2019-2025 | Rytary, Crexont, Lyvispah |
| Genentech USA, INC. | $1,073.11 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Lilly USA, LLC | $1,047.13 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Argenx US, INC. | $920.94 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $749.00 | 2019-2025 | Nuplazid |
| Allergan, INC. | $662.54 | 2019-2022 | |
| Eisai INC. | $647.13 | 2022-2025 | |
| Pfizer INC. | $589.61 | 2023-2025 |
Show all 83 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.